Technical Analysis for PRLD - Prelude Therapeutics Incorporated

Grade Last Price % Change Price Change
C 74.43 -2.76% -2.11
PRLD closed down 2.76 percent on Friday, January 22, 2021, on 89 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical PRLD trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -2.76%
Up 3 Days in a Row Strength -2.76%
20 DMA Support Bullish -1.65%
NR7 Range Contraction -1.65%
NR7-2 Range Contraction -1.65%
Inside Day Range Contraction -1.65%
Wide Bands Range Expansion -1.65%
20 DMA Support Bullish -0.16%
Older End-of-Day Signals for PRLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Prelude Therapeutics Incorporated Description

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Solid Tumors Cancers Lymphoma Wilmington Blastoma Glioblastoma Tyrosine Kinase Receptors Protein Kinase Inhibitors Small Molecule Therapies Phosphoinositide 3 Kinase Inhibitor Glioblastoma Multiforme

Is PRLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 89.06
52 Week Low 24.0
Average Volume 216,061
200-Day Moving Average 0.00
50-Day Moving Average 62.86
20-Day Moving Average 73.59
10-Day Moving Average 72.59
Average True Range 6.06
ADX 25.22
+DI 25.56
-DI 20.76
Chandelier Exit (Long, 3 ATRs ) 70.87
Chandelier Exit (Short, 3 ATRs ) 71.96
Upper Bollinger Band 87.97
Lower Bollinger Band 59.21
Percent B (%b) 0.53
BandWidth 39.08
MACD Line 2.90
MACD Signal Line 3.17
MACD Histogram -0.2715
Fundamentals Value
Market Cap 3.25 Billion
Num Shares 43.7 Million
EPS
Price-to-Sales 0.00
Price-to-Book 9.76
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.05
Resistance 3 (R3) 84.01 80.78 82.44
Resistance 2 (R2) 80.78 78.33 80.79 81.91
Resistance 1 (R1) 77.60 76.82 75.99 77.64 81.37
Pivot Point 74.37 74.37 73.56 74.38 74.37
Support 1 (S1) 71.19 71.92 69.58 71.23 67.49
Support 2 (S2) 67.96 70.41 67.97 66.95
Support 3 (S3) 64.78 67.96 66.42
Support 4 (S4) 64.82